AAO: Association between GLP-1 receptor agonists and age-related macular degeneration explored
Crude odds ratios suggest an increased risk for age-related macular degeneration (AMD) in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, but this finding is reversed after adjustment for cardiometabolic confounding variables, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held Oct. 9 to 12 in New Orleans.
A study presented at the American Academy of Ophthalmology's annual meeting in New Orleans suggests a possible link between the use of GLP-1 receptor agonists and an increased risk of age-related macular degeneration (AMD). Researchers from the Carle Illinois College of Medicine analyzed data from over 300 million patients, focusing on 15.4 million who had used GLP-1 RA and 1.4 million with AMD.
Crude odds ratios indicated a higher risk for any AMD (1.68), dry AMD (1.89), and wet AMD (1.53) in GLP-1 RA users. However, after adjusting for various confounding factors like type 2 diabetes, hypertension, or hyperlipidemia, the association was reversed for most conditions, including wet AMD, with adjusted odds ratios dropping to 0.69, 0.65, and 0.63, respectively.
The researchers emphasize the need for further investigation into the relationship between GLP-1 medications and AMD, considering other underlying health conditions that may influence the results.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
